Clinical Trials Browser

Active not recruiting × Interventional × Salivary Gland Neoplasms × Clear all

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT02568267 2026-03-06

STARTRK-2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

403 enrolled 10 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT03781986 2026-03-03

APG-115 in Salivary Gland Cancer Trial

Phase 1/2 Active not recruiting

41 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT04325828 2026-02-13

YATAGARASU

Phase 2 Active not recruiting

31 enrolled 15 charts

Head & Neck

Salivary Gland Neoplasms

NCT04895735 2026-02-02

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Phase 2 Active not recruiting

45 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT02650401 2025-12-24

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 1 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT05669664 2025-11-10

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Phase 2 Active not recruiting

21 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT02253238 2025-11-06

Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients

Phase NA Active not recruiting

427 enrolled

Head & Neck

Dehydration, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Phase 2 Active not recruiting

64 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05608876 2025-08-07

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Phase 2 Active not recruiting

15 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT05010629 2025-05-31

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Phase 2 Active not recruiting

35 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Salivary Gland Neoplasms

NCT05694819 2025-05-22

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Active not recruiting

56 enrolled

Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05074940 2025-04-10

Amivantamab in Adenoid Cystic Carcinoma

Phase 2 Active not recruiting

18 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT01220583 2025-02-13

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Phase 2 Active not recruiting

252 enrolled

Head & Neck

Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Phase 1 Active not recruiting

7 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Clinical Trials

iPRIME

STARTRK-2

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

APG-115 in Salivary Gland Cancer Trial

YATAGARASU

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

STARTRK-NG

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

KEYNOTE 158

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Amivantamab in Adenoid Cystic Carcinoma

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer